Margetuximab

What Is Margetuximab?[edit | edit source]

Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).
Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).

Administer Margenza as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses.
On days when both Margenza and chemotherapy are to be administered, Margenza may be administered immediately after chemotherapy completion.

This medicine is available in fallowing doasage form: As injections: 250 mg/10 mL (25 mg/mL) in a single-dose vial

This medicine is available in fallowing brand namesː

Common possible side effects and laboratory abnormalities of this medicine include:

Margenza may lead to reductions in left ventricular ejection fraction (LVEF).
Evaluate cardiac function prior to and during treatment.
Discontinue Margenza treatment for a confirmed clinically significant decrease in left ventricular function.
Margenza can cause fetal harm when administered to a pregnant woman.
Advise patients of the risk and need for effective contraception.
If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Safety and effectiveness of Margenza have not been established in pediatric patients.

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light until time of use.
Do not freeze.
Do not shake.

This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it.

‎

Margetuximab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.